Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract

M. Fragoso, H. Tahi, S. E. Gautier, B. Duchesne, Z. V. Lallet, E. Hernandez, F. Villain, R. K. Parrish, J. M. Parel

Research output: Contribution to journalArticle

Abstract

Purpose. In vitro and in vivo safety and efficacy evaluation of a CDRi made of poly(D,L-lactide-co-glycolide) 50/50 and a 5-FU antimitotic. Methods. The flexible "C" shaped CDRi device (0.7mm cross-section, 21mm long) contains 2mg of 5-FU and was calculated to release 4.5p,g 5-FU/hr to maintain a = 10[j.g 5-FU/ml concentration in the capsular bag-anterior chamber space, well above therapeutic threshold (= 0.2[4.g/ml) and below toxic level (60|0.rn/ml). In vitro characteristics were assessed in an artificial eye at 36°C with an aqueous flow of 20M-l/min. (10 times normal). The device is inserted in the empty capsular bag using a 19ga instrument. 3 control groups: 6 rabbits without capsule polishing, 6 with capsule polishing, 6 with capsule polishing and a CDRi without 5-FU. A fourth group of 6 receives a 5-FU CDRi. Follow-up stops 1 week after the onset of secondary cataract and histology is performed. Result?. The CDRi released 5-FU for = 50 days m vitro. In vivo, the onset of secondary cataract in controls was =3 weeks. Implant biodégradation takes =100days. The pharmacological, clinical, and histological results of this ongoing study will be presented. Conclusion. The intraocular 5-FU concentrations and long term effect on comeal endothelium have to be further assessed. The 5-FU CDRi needs refinement for insertion though a 3mm corneal incision and is promising.

Original languageEnglish (US)
Pages (from-to)S144
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
StatePublished - 1997

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract'. Together they form a unique fingerprint.

  • Cite this

    Fragoso, M., Tahi, H., Gautier, S. E., Duchesne, B., Lallet, Z. V., Hernandez, E., Villain, F., Parrish, R. K., & Parel, J. M. (1997). Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract. Investigative Ophthalmology and Visual Science, 38(4), S144.